Hematological malignancies Cancer Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
Conditions
Interventions
Participants are volunteered to be divided into two groups.
1. Standard chemotherapy
2. Chemotherapy combined with autologous CIK infusion
Sponsors
Harbin Medical University First Affiliated Hospital (China)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Community-dwelling leukemia patients 2. 5 to 60 years old, who would volunteer to accept autologous CIK cell treatment 3. Volunteer to accept chemotherapy but reject autologous CIK cell treatment
Exclusion criteria
Exclusion criteria: 1. Previous history of severe cardiovascular disease (coronary arterial disease, stroke, etc) 2. Severe chronic disease with poor prognosis (liver disease, kidney disease, etc) 3. Illegal drug use or chronic alcoholism 4. Physical limitations, mental or intellectual disabilities 5. Any condition that may affect the development of this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Outcome of leukemia after CIK treatment at short-term follow up: 1 month, 3 months, 6 months and 1 year 2. Remission or relapse evaluation at long-term follow up: ?1 year, 2 years, 3 years, 4 years and 5 years (end of study) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Age, white blood cell (WBC) count, platelet count, hemoglobin (Hb) level, percentage of leukemia cells in bone marrow and absolute number in peripheral blood. Karyotypic findings with cytogenetic markers 2. Type of treatment, number of treatment cycles to achieve remission 3. Minimal residual disease evaluation with whole body PET/CT scan, in-vivo CIK cell function sites with FDG labeling PET/CT scan Measured at diagnosis, short-term and long-term follow up after treatment | — |
Countries
China
Outcome results
None listed